A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)

CONCLUSIONS: Catch-up vaccination with V114 in healthy individuals 7 months-17 years of age was generally well tolerated and immunogenic for all 15 serotypes, including those not contained in PCV13, regardless of prior pneumococcal vaccination. These results support V114 catch-up vaccination in children with incomplete or no PCV immunization per the recommended schedule.PMID:36150974 | DOI:10.1016/j.vaccine.2022.09.003

Source: Vaccine - September 23, 2022 Category: Allergy & Immunology Authors: Natalie Banniettis Jacek Wysocki Leszek Szenborn Wanatpreeya Phongsamart Punnee Pitisuttithum Mika R ämet Peter Richmond Yaru Shi Ron Dagan Lori Good Melanie Papa Robert Lupinacci Richard McFetridge Gretchen Tamms Clay Churchill Luwy Musey Kara Bickham V Source Type: research